

The Medical Letter[®]

on Drugs and Therapeutics

Volume 68

April 13, 2026

ISSUE No.
1752

IN THIS ISSUE

In Brief: A Bumetanide Nasal Spray (*Enbumyst*) for Edema..... p 62

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 68 (Issue 1752)

April 13, 2026

Take CME Exams

IN BRIEF

A Bumetanide Nasal Spray (*Enbumyst*) for Edema

Enbumyst (Corstasis), a nasal spray formulation of the loop diuretic bumetanide, has been approved by the FDA for (short-term) treatment of edema associated with congestive heart failure, renal disease (including nephrotic syndrome), or hepatic disease in adults. It is the first diuretic nasal spray formulation to become available in the US. Bumetanide has been available for years in oral and IV formulations.

Pronunciation Key

Bumetanide: byoo met' a nide" *Enbumyst*: en byoo' mist

LOOP DIURETICS – Loop diuretics (e.g., furosemide, bumetanide, torsemide) are more effective for management of edema than thiazide-type diuretics (e.g., hydrochlorothiazide). They are often administered intravenously in patients who require rapid diuresis or have edema that is resistant to high doses of oral diuretics.¹⁻³ IV loop diuretics are inexpensive, but they generally must be given by a healthcare professional.

Two subcutaneous formulations of furosemide administered via an on-body infusor (*Furoscix* and *Lasix ONYU*) are FDA-approved for short-term treatment of edema in adults with chronic heart failure. *Furoscix* is also approved for use in patients with edema due to chronic kidney disease (including nephrotic syndrome).^{4,5}

CLINICAL STUDIES – No new efficacy trials were required for FDA approval of *Enbumyst*. In an open-label, crossover pharmacokinetic study, peak bumetanide plasma concentrations and overall drug exposure were similar with oral and intranasal bumetanide, and the diuretic, natriuretic, and kaliuretic effects of intranasal bumetanide were similar to those with the oral and IV

formulations of the drug in 68 healthy subjects.⁶ No data are available on the use of intranasal bumetanide in patients with edema, but intranasal administration should be effective in patients with reduced absorption of oral diuretics due to gut edema.

ADVERSE EFFECTS – The most commonly reported adverse effects of intranasal bumetanide have been hypovolemia and headache.

DOSAGE, ADMINISTRATION, AND COST – *Enbumyst* is intended for short-term use; patients should be switched to oral diuretic therapy as soon as practical. The drug is supplied in cartons containing 12 nasal spray devices, each of which delivers a single spray containing 0.5 mg of bumetanide. The usual dosage is 0.5-2 mg (1-4 sprays) administered intranasally once daily. If multiple sprays are required for a single dose, alternating between nostrils is recommended. According to the label, one 0.5-mg spray can be substituted for 10 mg of IV furosemide. One carton of 12 devices costs \$1197.⁷ ■

1. Drugs for chronic heart failure. *Med Lett Drugs Ther* 2025; 67:81.
2. Y Ikeda et al. Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure. *ESC Heart Fail* 2021; 8:4067.
3. SS Suri and SV Pamboukian. Optimal diuretic strategies in heart failure. *Ann Transl Med* 2021; 9:517.
4. In brief: *Furoscix* - a subcutaneous furosemide infusor for heart failure. *Med Lett Drugs Ther* 2023; 65:14.
5. In brief: A second subcutaneous furosemide infusor (*Lasix ONYU*) for heart failure. *Med Lett Drugs Ther* 2026; 68:47.
6. AP Ambrosy et al. Randomized study comparing a novel intranasal formulation of bumetanide with oral and intravenous formulations. *Circulation* 2025; 151:737.
7. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.

PRESIDENT, EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **EDITOR IN CHIEF EMERITUS:** Mark Abramowicz, M.D.; **VICE PRESIDENT, ADMINISTRATION:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., B.C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected: 

Copyright 2026. ISSN 1523-2859

The
Medical
Letter